Navigation Links
New Scan May Help Find Aggressive Prostate Tumors
Date:1/27/2010

Process is among several that use a variation of MRI technology

WEDNESDAY, Jan. 27 (HealthDay News) -- A new imaging technology promises to achieve the long-sought goal of singling out prostate cancers that are life-threatening and require the most aggressive treatment, researchers report.

Magnetic resonance spectroscopy, which provides information about the metabolic chemistry of suspected cancerous tissue, gave good results in a small trial in which its readings were compared with those of current measures of prostate cancer danger, according to a report published Jan. 27 in Science Translational Medicine.

"We see a good correlation with pathology defined by those methods," said Leo L. Cheng, an assistant professor of radiology and pathology at Harvard Medical School and a researcher at Massachusetts General Hospital.

Prostate cancers are common among older men, but most of them are so slow-growing that they pose no danger to life. Current diagnostic techniques, which include readings of blood levels of a protein, prostate-specific antigen, cannot pick out the dangerous tumors. Doctors can take a tissue sample by doing a biopsy, but they often miss the small but deadly portion of the cancer that is growing aggressively enough to be life-threatening.

In 2005, Cheng and his colleagues found that magnetic resonance spectroscopy could distinguish cancerous from normal prostate tissue by their metabolic profiles. That's because cancerous tissue produces different chemicals than normal tissue.

Their new study used magnetic resonance spectroscopy on five cancerous prostate glands removed from men with the diagnosis. The results of the scans were compared with those of the standard technique, which judges a cancer by the degree of disorder produced by the malignancy. Five of seven regions identified as cancerous by that method scored high on a magnetic resonance spectroscopy malignancy index. The other two regions were near the outer edges of the glands, where exposure to air made the magnetic resonance results less clear.

The same kind of analysis can be done without removing the prostate glands, so Cheng and his colleagues are moving toward a trial that would more resemble the work now done by doctors.

"We are doing a validation study," Cheng said. "Once these data are verified, we need to work with the electronics people to develop more sensitive probes. Once that part is overcome, everything can be applied."

The validation study will take "optimistically, one to three months," Cheng said. Getting data showing that the technology can be used in human patients "will take some time, a year or two," he said.

When and if it comes to human trials, "the most urgent issue is to guide biopsies," Cheng said. "By taking a chemical spectrum of tissue, we may be able to do better than pathology to tell how aggressive a tumor is."

The technology currently requires a magnetic field far more powerful than those in magnetic resonance imaging devices in current medical use, and so part of the program at Massachusetts General Hospital is an effort to make the method usable in less powerful devices, he said.

Cheng's program is one of a number of efforts aimed at applying magnetic resonance imaging to prostate cancer diagnosis. Another already is available commercially, marketed by iCAD Inc., a New Hampshire-based company.

The iCAD technology uses "dynamic contrast-enhanced" imaging, said Marc Filerman, vice president of global marketing for the company. Gadolinium, a contrast agent, is injected into the prostate gland "to produce images that better highlight where the potentially cancerous lesion might be," he said.

Gadolinium concentrates in regions where there are fast-growing blood vessels that the voracious expansion of cancerous tissue requires, he said. "Those blood vessels are leaky, and the resulting images enable us to quantify a potentially cancerous lesion, to see the effect of treatment," Filerman said.

Work to improve existing technologies is continuing, he said. "What we are trying to do in the magnetic resonance imaging community is to standardize on the best methodology for image acquisition and interpretation," Filerman explained.

More information

The U.S. National Cancer Institute has more on prostate cancer.



SOURCES: Leo L. Cheng, Ph.D., assistant professor, radiology and pathology, Harvard Medical School, and researcher, Massachusetts General Hospital, Boston; Marc Filerman, vice president, global marketing, iCAD Inc., Nashua, N.H.; Jan. 27, 2010, Science Translational Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Marker for Aggressive Prostate Cancer Found
2. More Aggressive Treatment for Weekend Stroke
3. Genetic variant associated with aggressive form of prostate cancer
4. Protein link may be key to new treatment for aggressive brain tumor
5. Aggressive Infection Control Program Protects Cancer Patients from Acquiring Clinic-Based H1N1 Influenza
6. AdCare Health Systems Completes Private Placement to Fund Aggressive Growth Initiatives
7. Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkins Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
8. Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines
9. MS is more aggressive in children but slower to cause disability than in adults
10. Elderly Treated Less Aggressively for Heart Attack
11. Nations hip fracture rate could drop 25 percent with aggressive osteoporosis prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: